Blood tester, a non-invasive screening option Shield - Brand name or equal will be considered. IHS1522255v2
Summary
AI-generated · Apr 24, 2026Procure 120 ShieldTM blood testers, a non-invasive screening option FDA-approved for individuals at average risk for colorectal cancer; brand-name or equal will be considered. The contract covers a base year plus four option years, with anticipated usage of about 20 units per year (roughly 100 units total if all option years are exercised).
120 each The ShieldTM blood tester, a non-invasive screening option FDA approved for individuals at average risk for Colorectal cancer (CRC) - Brand name or equal will be considered. Base plus 4 years Service unit anticipates approximate same usage of 20 per year. All quotes should include a base plus 4 years at a amount of 20 per year of 100 over the potential of exercising all option years. Technical questions may be directed to Buffy.George@ihs.gov
From Combined Synopsis/Solicitation posted on Apr 23, 2026Notice history
1Details
Award Information
Not yet awarded
Contacts
Phone
Agency
Place of Performance
USA